(NASDAQ: IMNN) Imunon's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.96%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.23%.
Imunon's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast IMNN's revenue for 2026 to be $110,917,510, with the lowest IMNN revenue forecast at $110,917,510, and the highest IMNN revenue forecast at $110,917,510. On average, 1 Wall Street analysts forecast IMNN's revenue for 2027 to be $400,431,011, with the lowest IMNN revenue forecast at $400,431,011, and the highest IMNN revenue forecast at $400,431,011.
In 2028, IMNN is forecast to generate $817,781,643 in revenue, with the lowest revenue forecast at $817,781,643 and the highest revenue forecast at $817,781,643.